Concentrations of metalloproteinase-1 in patients with morphea treated with phototherapy: a preliminary study
Anna Malewska-Woźniak1, Martha Lodyga1, Zygmunt Adamski1
1Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.
Introduction:
Morphea (localized scleroderma) is a rare, chronic, inflammatory connective tissue disease, characterized by immune system dysfunction, vasculopathy and skin fibrosis. One of the most effective treatments is phototherapy. Phototherapy has been found to be effective in treating localized scleroderma by inducing the expression of metalloproteinase-1.
Aim:
To compare the concentrations of metalloproteinase (MMP-1) before psoralen and ultraviolet A (PUVA) and ultraviolet A1 (UVA1) treatments in the serum of patients with morphea.
Material And Methods:
The observational study was conducted in one research centre and included patients with generalised morphea who were treated with PUVA and UVA1 phototherapies. The mean age of all morphea patients included in the study was 55.7 years. The levels of MMP-1 were examined by ELISA (The Biorbyt Human MMP-1 ELISA - Enzyme-Linked Immunosorbent Assay).
Results:
The study showed that patients treated with PUVA and UVA1 had an improvement based on clinical measures, resulting in a reduction of clinical score. However, we did not observe statistically significant differences in MMP-1 concentrations before and after treatment. Limitations: The study sample was relatively small. Further studies on a larger group of patients would be beneficial.
Conclusions:
Our data suggest that there is a possible correlation between MMP-1 concentrations and phototherapy. MMP-1 levels were found to be increased following phototherapy treatment, which may suggest a correlation with better response to treatment in patients with morphea. However, further research is needed.
Insights
Phototherapy effectively treats morphea (localized scleroderma), potentially by increasing metalloproteinase-1 (MMP-1). While clinical improvement was observed, MMP-1 levels did not significantly change before and after psoralen and ultraviolet A (PUVA) or ultraviolet A1 (UVA1) treatments.
Area of Science:
- Dermatology
- Immunology
- Biochemistry
Background:
- Morphea, a rare connective tissue disease, involves immune dysfunction, vasculopathy, and skin fibrosis.
- Phototherapy is an effective treatment for localized scleroderma, potentially by influencing metalloproteinase-1 (MMP-1) expression.
Purpose of the Study:
- To compare serum metalloproteinase-1 (MMP-1) concentrations in morphea patients before and after psoralen and ultraviolet A (PUVA) and ultraviolet A1 (UVA1) treatments.
- To investigate the potential correlation between MMP-1 levels and phototherapy response in morphea.
Main Methods:
- An observational study involving generalized morphea patients treated with PUVA and UVA1 phototherapies.
- Serum MMP-1 levels were quantified using Enzyme-Linked Immunosorbent Assay (ELISA).
Main Results:
- Patients showed clinical improvement with reduced scores after PUVA and UVA1 treatments.
- No statistically significant differences in MMP-1 concentrations were observed before and after phototherapy.
- A trend of increased MMP-1 levels post-treatment was noted.
Conclusions:
- Phototherapy may correlate with MMP-1 levels in morphea patients.
- Increased MMP-1 following phototherapy might indicate a better treatment response.
- Further research with larger patient cohorts is recommended to validate these findings.
